Lung cancer has high morbidity and mortality rates worldwide.1 The most common type of lung cancer is non-small cell lung cancer (NSCLC).2 Currently, first-line treatment options for unresectable NSCLC without driver mutations include chemotherapy, anti-PD-1/PD-L1 immunotherapy, and chemotherapy combined with immunotherapy.3 Advanced NSCLC with driver gene mutations, such as epidermal growth factor receptor (EGFR) mutations, are treated with targeted therapies, such as epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).3 This evidence concerns the gene CD274 and lung cancer.